Drugs / BI 1026706
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials · 3 missed | ||||||
| Phase 1 | NCT02652416 | Sep → Dec 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02657408 | Mar 2016 → Feb 2017 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02642614 | Jan → Jun 2016 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02513446 | Sep → Nov 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02126826 | May → Oct 2014 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02084511 | Mar → Oct 2014 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02037165 | Jan → Apr 2014 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01763333 | Jan → Sep 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02732951 | Apr 2016 → Oct 2017 | macular retinal edema | Boehringer Ingelheim | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1026706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02642614 ↗ |
| Action | Inhibit | “BI 1026706, a potent B1R antagonist, was hypothesized to reduce the inflammatory activity after segmental lipopolysaccharide (LPS) challenge in humans due to decreased...” PMID 37562641 ↗ Aug 2023 |
| Route | Oral | “BI 1026706 oral solution” NCT02037165 ↗ |